Market Place
Sourcing Support
Royalty bestows Zenas with $300M for Autoimmune Approval Push
02 Sep 2025 //
FIERCE BIOTECH
Zenas BioPharma to Present at Healthcare Investor Conferences
26 Aug 2025 //
GLOBENEWSWIRE
Zenas BioPharma Reveals Q2 Financial Results & Corporate News
12 Aug 2025 //
GLOBENEWSWIRE
Zenas BioPharma Inducement Grant Under Nasdaq Rule 5635(c)(4)
20 Jun 2025 //
GLOBENEWSWIRE
Zenas BioPharma to Present at Jefferies Healthcare Conference
29 May 2025 //
GLOBENEWSWIRE
Zenas BioPharma Reports Q1 2025 Financial Results and Updates
15 May 2025 //
GLOBENEWSWIRE
Zenas Bio Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
17 Apr 2025 //
GLOBENEWSWIRE
Zenas BioPharma names Haley Laken Chief Scientific Officer
07 Apr 2025 //
GLOBENEWSWIRE
Zenas BioPharma names Lisa von Moltke, M.D., Head of R&D and CMO
17 Mar 2025 //
GLOBENEWSWIRE
Zenas Bio Announces 2024 Accomplishments & Autoimmune Therapies
05 Feb 2025 //
GLOBENEWSWIRE
Zenas Bio to Present at Guggenheim SMID Cap Biotech Conference
28 Jan 2025 //
GLOBENEWSWIRE
Zenas Completes INDIGO Trial Enrollment in IgG4-RD
12 Nov 2024 //
GLOBENEWSWIRE
Zenas BioPharma Reports Q3 2024 Financial Results & Updates
12 Nov 2024 //
GLOBENEWSWIRE
Zenas BioPharma to Attend Upcoming Healthcare Investor Conferences
07 Nov 2024 //
GLOBENEWSWIRE
Zenas BioPharma Announces Closing Of Full Option Exercise
19 Sep 2024 //
GLOBENEWSWIRE
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
12 Sep 2024 //
GLOBENEWSWIRE
Zenas BioPharma raises $225 mln in US IPO
12 Sep 2024 //
REUTERS
Zenas BioPharma Seeks $689.7M Valuation In US IPO
06 Sep 2024 //
REUTERS
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO
22 Aug 2024 //
REUTERS
Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer
01 Jul 2024 //
GLOBENEWSWIRE
Zenas Announces $200M Series C For Immunology Programs
07 May 2024 //
GLOBENEWSWIRE
Lonnie Moulder`s Zenas closes a $200M Series C to drug`s autoimmune potential
07 May 2024 //
ENDPTS
Zenas bags $200M series C to reach a handful of key mAB readouts
07 May 2024 //
FIERCE BIOTECH
Zenas BioPharma Appoints Patricia Allen to its Board of Directors
06 Mar 2024 //
GLOBENEWSWIRE
Zenas BioPharma Strengthens Executive Leadership
04 Dec 2023 //
GLOBENEWSWIRE
Zenas BioPharma Announces Strategic License and Collaboration Agreement with BMS
06 Sep 2023 //
PRESS RELEASE
Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab
01 Aug 2023 //
GLOBENEWSWIRE
Zenas Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab
11 Jan 2023 //
GLOBENEWSWIRE
Zenas zips up $118M series B to launch phase 3 trial
08 Nov 2022 //
FIERCEBIOTECH
Zenas BioPharma Secures $118 M to Advance Broad Pipeline of Autoimmune Disease
07 Nov 2022 //
GLOBENEWSWIRE
Zenas BioPharma Obtains IND Approval in China for PI/II Study of ZB001
01 Aug 2022 //
GLOBENEWSWIRE
Zenas BioPharma Obtains IND Approval in China for PI/II Study of ZB001
31 Jul 2022 //
GLOBENEWSWIRE
Zenas BioPharma Submits IND Application in China for ZB001 for TED
15 May 2022 //
GLOBENEWSWIRE
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
20 Nov 2021 //
BUSINESSWIRE
Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company
23 Mar 2021 //
GLOBENEWSWIRE
